The retrospective cohort study of 545 patients with MM treated with anti-PD1 +/- anti-CTLA4 showed no significant difference in ORR, PFS or OS between patients treated with combination anti-PD1 and anti-CTLA4 and patients treated with Anti-PD1 alone. This evidence concerns the gene CTLA4 and Miyoshi myopathy.